The UK was the leader for innovation capital in 2015: total funding was 2.4 billion dollars, venture funding was 884 million dollars and 87 investments were made.

Ireland took second place in total investment: 1.7 billion dollars)

France (782 million dollars) & Belgium (781 million dollars) came in third and fourth place for total investment

Switzerland (381 million dollars) and Germany (270 million dollars) came in second and third place in venture funding

IPOS: 33 European companies went public in 2015, total fundraising via IPOS was 1.4 billion dollars and the average amount raised was 42 million dollars.

2014: European Biotechnology in Numbers

2014 was a successful year for biotech, increases in R&D, revenues, IPOS, capital and market capitalisation were especially prominent. In fact, it was European biotech’s strongest performance in the history of the industry. We’ve based ourselves entirely on the EY Beyond Borders 2015 report to bring this information to you.

European biotech companies’ aggregate net income increased by 199% to 3.3 billion dollars;

European biotech companies added 533 million dollars in aggregate net income, which was a 52% annual increase;

2014 was a strong year for financing performance – in fact it was the strongest performance in the history of the industry.

The market capitalisations of European biotech companies increased. 59% of European biotechs saw an increase in their market caps;

31 European biotech companies made their start in public exchanges (including exchanges located in the US). The number of European public biotech companies increased by 20%. These new listings participated 1% to the continent’s revenue growth and 39% to the upsurge in R&D expenditures;

2014 was a good year for commercial leaders; they were responsible for 77% of the annual revenue growth.

The financial performance of Europe’s non-commercial leaders increased and surpassed the commercial leaders in terms of R&D and revenue;

Smaller European biotech companies’ revenues increased by 717 million dollars;

Non-commercial leaders increased their R&D expenditures by a total of 401 million dollars, the commercial leaders increased by 256 million dollars;

European innovation capital was 6.5 billion dollars. Venture investment was responsible for 31% of the total.

What will 2016 bring?

Over the years biotech companies have acquired a lot of cash due to venture capital firms raising new funds. Operations will continue and promising new treatments from companies who can demonstrate how patients profit from the latter will be able to attract cash.

Source: IPOS: The times they are are a-changin’ – European Biotechnology : Spring Edition, Vol.15, 2016